Characteristics of patients who underwent apheresis (N = 148) and those who received CAR T-cell therapy (N = 124)
| . | Apheresis (N = 148) . | CAR T-cell infusion (N = 124) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic . | All patients (N = 148) . | No BT (n = 67) . | BT (n = 81) . | P . | All patients (N = 124) . | No BT (n = 62) . | BT (n = 62) . | P . |
| Age, y | .88 | .59 | ||||||
| Median | 60 | 60 | 59 | 60 | 60 | 60 | ||
| Range | 18-85 | 18-84 | 18-85 | 18-85 | 18-84 | 18-85 | ||
| >60 | 76 (51) | 36 (54) | 40 (49) | .62 | 64 (52) | 32 (52) | 32 (52) | 1.00 |
| Female sex | 42 (28) | 21 (31) | 21 (26) | .47 | 32 (26) | 18 (29) | 14 (23) | .54 |
| ECOG PS 2-3 | 30 (20) | 7 (10) | 23 (28) | .01 | 17 (14) | 4 (7) | 13 (21) | .03 |
| Pathology | .78 | .61 | ||||||
| DLBCL | 115 (78) | 52 (78) | 63 (78) | 95 (77) | 49 (79) | 46 (74) | ||
| TFL | 24 (16) | 10 (15) | 14 (17) | 20 (16) | 8 (13) | 12 (19) | ||
| PMBCL | 9 (6) | 5 (8) | 4 (5) | 9 (7) | 5 (8) | 4 (7) | ||
| Cell of origin | .57 | .32 | ||||||
| GCB | 86 (58) | 36 (54) | 50 (62) | 72 (58) | 32 (51) | 40 (65) | ||
| Non-GCB | 55 (37) | 28 (42) | 27 (33) | 46 (37) | 27 (44) | 19 (31) | ||
| Unknown | 7 (5) | 3 (5) | 4 (5) | 6 (5) | 3 (5) | 3 (5) | ||
| Double expresser | .31 | .56 | ||||||
| Yes | 45 (30) | 18 (27) | 27 (33) | 36 (29) | 16 (26) | 20 (32) | ||
| No | 76 (51) | 39 (58) | 37 (46) | 68 (55) | 37 (60) | 31 (50) | ||
| Unknown | 27 (18) | 10 (15) | 17 (21) | 20 (16) | 9 (14) | 11 (18) | ||
| HGBL-DH/TH | .11 | .09 | ||||||
| Yes | 30 (20) | 9 (13) | 21 (26) | 23 (19) | 7 (11) | 16 (26) | ||
| No | 107 (72) | 54 (81) | 53 (65) | 92 (74) | 51 (82) | 41 (661) | ||
| Unknown | 11 (7) | 4 (6) | 7 (8.6) | 9 (7) | 4 (7) | 5 (8) | ||
| Stage at apheresis | .14 | .20 | ||||||
| I/II | 19 (13) | 12 (18) | 7 (9) | 18 (15) | 12 (19) | 6 (10) | ||
| III/IV | 129 (87) | 55 (82) | 74 (81) | 106 (85) | 50 (81) | 56 (91) | ||
| IPI ≥3 | 88 (60) | 30 (45) | 58 (72) | <.01 | 68 (55) | 27 (44) | 41 (66) | .02 |
| Bulky disease (≥10 cm) | 46 (31) | 14 (21) | 32 (40) | .01 | 33 (27) | 11 (18) | 22 (36) | .04 |
| Lines of prior therapy, n | .55 | .39 | ||||||
| Median | 3 | 3 | 3 | 3 | 3 | 3 | ||
| Range | 2-11 | 2-11 | 2-9 | 2-11 | 2-11 | 2-9 | ||
| ≥3 | 110 (74) | 47 (70) | 63 (78) | .35 | 87 (71) | 43 (69) | 44 (71) | 1.00 |
| Serum LDH, IU/L* | ||||||||
| >ULN | 110 (74) | 41 (61) | 69 (85) | <.01 | 87 (71) | 37 (60) | 50 (81) | .01 |
| >2× ULN | 45 (32) | 11 (17) | 34 (44) | <.01 | 26 (22) | 8 (13) | 18 (31) | .03 |
| Median time from leukapheresis to axi-cel infusion, d | 29.0 | 29.5 | 29.0 | 1.00 | ||||
| . | Apheresis (N = 148) . | CAR T-cell infusion (N = 124) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic . | All patients (N = 148) . | No BT (n = 67) . | BT (n = 81) . | P . | All patients (N = 124) . | No BT (n = 62) . | BT (n = 62) . | P . |
| Age, y | .88 | .59 | ||||||
| Median | 60 | 60 | 59 | 60 | 60 | 60 | ||
| Range | 18-85 | 18-84 | 18-85 | 18-85 | 18-84 | 18-85 | ||
| >60 | 76 (51) | 36 (54) | 40 (49) | .62 | 64 (52) | 32 (52) | 32 (52) | 1.00 |
| Female sex | 42 (28) | 21 (31) | 21 (26) | .47 | 32 (26) | 18 (29) | 14 (23) | .54 |
| ECOG PS 2-3 | 30 (20) | 7 (10) | 23 (28) | .01 | 17 (14) | 4 (7) | 13 (21) | .03 |
| Pathology | .78 | .61 | ||||||
| DLBCL | 115 (78) | 52 (78) | 63 (78) | 95 (77) | 49 (79) | 46 (74) | ||
| TFL | 24 (16) | 10 (15) | 14 (17) | 20 (16) | 8 (13) | 12 (19) | ||
| PMBCL | 9 (6) | 5 (8) | 4 (5) | 9 (7) | 5 (8) | 4 (7) | ||
| Cell of origin | .57 | .32 | ||||||
| GCB | 86 (58) | 36 (54) | 50 (62) | 72 (58) | 32 (51) | 40 (65) | ||
| Non-GCB | 55 (37) | 28 (42) | 27 (33) | 46 (37) | 27 (44) | 19 (31) | ||
| Unknown | 7 (5) | 3 (5) | 4 (5) | 6 (5) | 3 (5) | 3 (5) | ||
| Double expresser | .31 | .56 | ||||||
| Yes | 45 (30) | 18 (27) | 27 (33) | 36 (29) | 16 (26) | 20 (32) | ||
| No | 76 (51) | 39 (58) | 37 (46) | 68 (55) | 37 (60) | 31 (50) | ||
| Unknown | 27 (18) | 10 (15) | 17 (21) | 20 (16) | 9 (14) | 11 (18) | ||
| HGBL-DH/TH | .11 | .09 | ||||||
| Yes | 30 (20) | 9 (13) | 21 (26) | 23 (19) | 7 (11) | 16 (26) | ||
| No | 107 (72) | 54 (81) | 53 (65) | 92 (74) | 51 (82) | 41 (661) | ||
| Unknown | 11 (7) | 4 (6) | 7 (8.6) | 9 (7) | 4 (7) | 5 (8) | ||
| Stage at apheresis | .14 | .20 | ||||||
| I/II | 19 (13) | 12 (18) | 7 (9) | 18 (15) | 12 (19) | 6 (10) | ||
| III/IV | 129 (87) | 55 (82) | 74 (81) | 106 (85) | 50 (81) | 56 (91) | ||
| IPI ≥3 | 88 (60) | 30 (45) | 58 (72) | <.01 | 68 (55) | 27 (44) | 41 (66) | .02 |
| Bulky disease (≥10 cm) | 46 (31) | 14 (21) | 32 (40) | .01 | 33 (27) | 11 (18) | 22 (36) | .04 |
| Lines of prior therapy, n | .55 | .39 | ||||||
| Median | 3 | 3 | 3 | 3 | 3 | 3 | ||
| Range | 2-11 | 2-11 | 2-9 | 2-11 | 2-11 | 2-9 | ||
| ≥3 | 110 (74) | 47 (70) | 63 (78) | .35 | 87 (71) | 43 (69) | 44 (71) | 1.00 |
| Serum LDH, IU/L* | ||||||||
| >ULN | 110 (74) | 41 (61) | 69 (85) | <.01 | 87 (71) | 37 (60) | 50 (81) | .01 |
| >2× ULN | 45 (32) | 11 (17) | 34 (44) | <.01 | 26 (22) | 8 (13) | 18 (31) | .03 |
| Median time from leukapheresis to axi-cel infusion, d | 29.0 | 29.5 | 29.0 | 1.00 | ||||
Values are n (%) unless otherwise noted. P values in bold indicate statistical significance (≤.05).
ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B-cell type; HGBL-DH/TH, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; LDH, lactate dehydrogenase; PMBCL, primary mediastinal B-cell lymphoma; TFL, transformed follicular lymphoma; ULN, upper limit of normal.
LDH data unavailable for 5 patients.